Nasta, Nafiza .
HRN: 15-10-33 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/05/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
10/05/2025
10/12/2025
IV
1.5 G
Q8
Mastitis
Waiting Final Action
Indication: Prophylaxis Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes